List view / Grid view

Issue #2 2015

Filter the results



The importance of adequately triaging hits from HTS campaigns

19 June 2015 | By , ,

High throughput screening (HTS) continues to be employed in drug discovery as the primary source of identifying chemical starting points for drug discovery and tool compounds for chemical biology, respectively. Although small molecule drug discovery efforts have focused largely upon enzyme, receptor and ion-channel targets, there has been an increase…


Investigation of venom use in stem cell differentiation

16 June 2015 | By ,

Stem cells differentiate to form more than 200 specialised cells, including erythroid bodies, haematopoietic cells, myogenic cells, neural cells, signalling cells and structural cells, such as hepatocytes. Differentiation of stem cells triggers a number of variable changes in the cell, such as membrane potential, responsiveness to signal, metabolic activities, and…


Human pluripotent stem cell-derived cardiomyocytes in drug discovery and development

12 June 2015 | By , ,

Procedures for cardiac differentiation of human pluripotent stem cells (hPSCs) have greatly improved over the past few years. The facilitated derivation of hPSC-cardiomyocytes has enabled the thorough assessment of their physiology and manipulation of their properties. Moreover, patient-specific hPSCs generated through cellular reprogramming allow for cardiac disease modelling, discovery of…


Stem Cells In-Depth Focus 2015

10 June 2015 | By Kenji Schorpp, Kamyar Hadian, Sheraz Gul, Horst Flotow

This Stem Cells In-Depth Focus features articles on stem cell-derived cardiomyocytes, and their use in drug discovery and development, as well as a look at how venom could be used in stem cell differentiation...


Screening In-Depth Focus 2015

10 June 2015 | By Kenji Schorpp, Kamyar Hadian, Sheraz Gul, Horst Flotow

In this Screening In-Depth Focus, high throughput screening is the topic focused on by Kenji Schorpp and Kamyar Hadian, Institute of Molecular Toxicology and Pharmacology, and Sheraz Gul, Fraunhofer Institute for Molecular Biology and Applied Ecology. They discuss the importance of the technique in drug discovery today as well as…


Developing antibody therapeutics

10 June 2015 | By

Monoclonal antibodies have come of age as therapeutics; there are now more than 30 antibodies on the market and over 200 in clinical trials. The attractions of therapeutic antibodies lie not only in their potential to make potent drugs but also their relative low risk in comparison to small molecule…